本文選題：藥品零售連鎖 + 環(huán)境分析��； 參考：《山西大學(xué)》2016年碩士論文

【摘要】：隨著中國(guó)藥品經(jīng)濟(jì)的快速發(fā)展、醫(yī)療制度的改革和開(kāi)放藥品市場(chǎng)的不斷深化,山西藥品零售行業(yè)正面臨著巨大的機(jī)遇和挑戰(zhàn)。2015年,全國(guó)藥品分銷(xiāo)市場(chǎng)整體看來(lái)還不錯(cuò),但增長(zhǎng)速度有所放緩、利潤(rùn)空間不斷縮小將持續(xù)存在,藥品連鎖零售的集中度有待提高。2015年6月,商務(wù)部發(fā)布了《2014年藥品流通行業(yè)運(yùn)行統(tǒng)計(jì)分析報(bào)告》,報(bào)告顯示2014年,我國(guó)的藥品流通行業(yè)銷(xiāo)售總額達(dá)15021億元,這其中,藥品零售市場(chǎng)完成3004億元。截至2013年底,全國(guó)藥房門(mén)店總數(shù)達(dá)43.26萬(wàn)家,藥品連鎖零售企業(yè)3570家,下轄門(mén)店15.82萬(wàn)家,單體零售藥房27.44萬(wàn)家。這些數(shù)據(jù)與前幾年相比又有發(fā)展和增長(zhǎng)。此外,電子商務(wù)全面高速地發(fā)展,也吸引了越來(lái)越多的制藥企業(yè)開(kāi)始選擇依靠電子商務(wù)來(lái)尋求新的機(jī)遇。2015年,國(guó)內(nèi)網(wǎng)上藥店銷(xiāo)售額達(dá)到40多億元,京東,天貓,當(dāng)當(dāng),1號(hào)店等電商巨頭紛紛加入到藥品B2C的競(jìng)爭(zhēng)之中。傳統(tǒng)藥房不得不謹(jǐn)慎對(duì)待這一形勢(shì)。在"新醫(yī)改"的作用下,"大醫(yī)療時(shí)代"已成為我國(guó)醫(yī)藥行業(yè)當(dāng)前最主要的特點(diǎn)。國(guó)家不斷出臺(tái)各種相關(guān)政策,市場(chǎng)增長(zhǎng)速度正在不斷放緩,業(yè)內(nèi)人士預(yù)計(jì)在不久的將來(lái),藥企必須面對(duì)越來(lái)越困難的盈利模式。此外,分散的市場(chǎng)必然帶來(lái)兼并、重組等行業(yè)"大動(dòng)作",藥品零售行業(yè)的集中度還會(huì)提升。由于政策因素的影響逐漸增加,消費(fèi)者消費(fèi)觀念的改變,藥品零售市場(chǎng)上的種類(lèi)也會(huì)隨之變化�！DWM藥房連鎖有限公司是一家民營(yíng)藥品零售連鎖企業(yè),自2003年成立以來(lái),始終扛著"平價(jià)藥房"的大旗在與傳統(tǒng)的藥房做競(jìng)爭(zhēng)。該企業(yè)經(jīng)過(guò)十幾年的發(fā)展,已成為山西本土藥品連鎖企業(yè)的領(lǐng)軍人物,特別是2011年與國(guó)務(wù)院國(guó)資委直屬的世界500強(qiáng)企業(yè)中國(guó)藥品集團(tuán)旗下的國(guó)大藥房成功重組,成立山西GDWM藥房連鎖有限公司,建立了更加強(qiáng)大的藥品連鎖零售體系。本文以GDWM藥房為例,對(duì)山西本土藥品零售連鎖企業(yè)的發(fā)展戰(zhàn)略進(jìn)行了研究,其中著重研究了本土連鎖藥房所具有的優(yōu)勢(shì)和劣勢(shì),以及面臨的機(jī)會(huì)和挑戰(zhàn),試圖通過(guò)為GDWM藥房制定適宜的應(yīng)對(duì)戰(zhàn)略,讓其在當(dāng)前越來(lái)越復(fù)雜的市場(chǎng)和激烈的競(jìng)爭(zhēng)中占據(jù)主動(dòng)位置,搶得先機(jī)。同時(shí),本文的客觀分析也為與GDWM藥房相似的本土其他藥品連鎖企業(yè)是否能構(gòu)合理配置資源、合作共贏、"抱團(tuán)取暖"提供了可供參考研究方向和內(nèi)容。
[Abstract]:With the rapid development of China's drug economy, the reform of the medical system and the deepening of the opening up of the pharmaceutical market, the drug retail industry in Shanxi is facing enormous opportunities and challenges. In 2015, the national drug distribution market as a whole looks good. However, the growth rate has slowed, profit margins will continue to shrink, and the concentration of drug chain retailing needs to be improved. In June 2015, the Ministry of Commerce released the Statistical Analysis report on the Operation of the Drug Circulation Industry in 2014, which shows that in 2014, China's drug circulation industry sales to 1.5021 trillion yuan, which, drug retail market completed 300.4 billion yuan. By the end of 2013, there were 432600 pharmacies nationwide, 3570 drug chains, 158200 stores and 274400 retail stores. These figures are growing and growing compared with previous years. In addition, the rapid development of e-commerce has attracted more and more pharmaceutical enterprises to choose to rely on e-commerce to seek new opportunities. In 2015, the sales of domestic online pharmacies reached more than 4 billion yuan, JingDong, Tmall, Dangdang, No.1 store and other e-commerce giants have joined the pharmaceutical B-2 C competition. Traditional pharmacies have to be cautious about the situation. Under the action of "New Medical Reform", "Great Medical Age" has become the most important feature of Chinese medicine industry. Market growth is slowing, and industry insiders expect drug companies to face increasingly difficult profit models in the near future. In addition, the decentralized market will inevitably bring mergers, restructuring and other industries "big action", drug retail industry concentration will also increase. As the influence of policy factors increases gradually and consumer consumption concept changes, so will the variety in the drug retail market. GDWM Pharmacy chain Co., Ltd. is a private drug retail chain company, which has been established since 2003. Always carrying the flag of "parity pharmacy" in the competition with the traditional pharmacy. After more than ten years of development, this enterprise has become a leading figure in local drug chain enterprises in Shanxi, especially the successful reorganization in 2011 with the National Congress Pharmacy of the China National Pharmaceutical Group, a world 500 leading enterprise directly under the State Administration and Administration Commission of the State Council. Established Shanxi GDWM Pharmacy chain Co., Ltd. to establish a more powerful drug chain retail system. Taking GDWM pharmacy as an example, this paper studies the development strategy of local drug retail chain enterprises in Shanxi Province, and focuses on the advantages and disadvantages of local chain pharmacies, as well as the opportunities and challenges they face. This paper attempts to make appropriate coping strategy for GDWM pharmacy, so that it can take the initiative position in the increasingly complex market and fierce competition. At the same time, the objective analysis of this paper also provides a reference for the local drug chain enterprises similar to the GDWM pharmacy whether they can reasonably allocate resources, cooperate and win together, and provide reference for the research direction and content of "Baotuan heating".
【學(xué)位授予單位】：山西大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類(lèi)號(hào)】：F721;F272

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 解芳;李東輝;;國(guó)內(nèi)藥品連鎖超市消費(fèi)者滿(mǎn)意度調(diào)查及對(duì)策分析——基于西安市977份街頭及網(wǎng)上問(wèn)卷調(diào)查[J];經(jīng)營(yíng)管理者;2015年33期

2 于洪鳳;;基于SWOT分析的連鎖藥店競(jìng)爭(zhēng)力提升策略研究[J];科學(xué)中國(guó)人;2014年18期

3 吳錦;徐蕓;;我國(guó)連鎖藥店多元化經(jīng)營(yíng)存在的問(wèn)題及對(duì)策研究[J];中小企業(yè)管理與科技(下旬刊);2013年03期

4 祝歡超;馮國(guó)忠;;現(xiàn)階段我國(guó)網(wǎng)上藥店SWOT分析[J];現(xiàn)代商貿(mào)工業(yè);2013年06期

5 李靜;朱昌蕙;何明霞;王媛;;淺議新醫(yī)改形勢(shì)下零售藥店的經(jīng)營(yíng)策略[J];現(xiàn)代預(yù)防醫(yī)學(xué);2011年12期

6 林新波;;藥品連鎖零售企業(yè)的情感營(yíng)銷(xiāo)[J];銷(xiāo)售與市場(chǎng)(管理版);2011年06期

7 吳紅雁;;現(xiàn)階段我國(guó)零售藥店SWOT分析及營(yíng)銷(xiāo)策略[J];齊魯藥事;2010年11期

8 朱增智;;從經(jīng)濟(jì)學(xué)視角看上海平價(jià)藥房新聞公關(guān)策略——以“開(kāi)心人”大藥房為例[J];科技廣場(chǎng);2008年02期

9 黃君發(fā);;萬(wàn)民藥房:藥品零售試驗(yàn)場(chǎng)[J];當(dāng)代經(jīng)理人;2007年04期

10 邱童;李t，

本文編號(hào)：2020332